Management of postradiation late hemorrhage following treatment for HPV-positive oropharyngeal squamous cell carcinoma

被引:1
|
作者
Stevens, Madelyn N. [1 ]
Gallant, Jean-Nicolas [1 ]
Feldman, Michael J. [2 ]
Sermarini, Anthony J. [3 ]
Cmelak, Anthony [4 ]
Murphy, Barbara [5 ]
Langerman, Alexander [1 ]
Kim, Young [1 ]
Rohde, Sarah L. [1 ]
Mannion, Kyle [1 ]
Sinard, Robert J. [1 ]
Netterville, James L. [1 ]
Chitale, Rohan [2 ]
Topf, Michael C. [1 ]
机构
[1] Vanderbilt Univ, Dept Otolaryngol Head & Neck Surg, Med Ctr, 1215 21st Ave S,7th Floor, Nashville, TN 37323 USA
[2] Vanderbilt Univ, Dept Neurosurg, Med Ctr, Nashville, TN 37323 USA
[3] Vanderbilt Univ, Sch Med, Nashville, TN 37323 USA
[4] Vanderbilt Univ, Dept Radiat Oncol, Med Ctr, Nashville, TN 37323 USA
[5] Vanderbilt Ingram Canc Ctr, Dept Med Oncol, Nashville, TN USA
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2022年 / 44卷 / 05期
关键词
hemorrhage; HPV-positive squamous cell carcinoma; oropharyngeal; postradiation; CAROTID BLOWOUT; HUMAN-PAPILLOMAVIRUS; NECK-CANCER; HEAD; TRENDS; RISK;
D O I
10.1002/hed.27001
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background Acute oropharyngeal hemorrhage is a serious complication for patients with oropharyngeal squamous cell carcinoma (OPSCC), particularly in patients with a history of radiation therapy (RT). Methods Retrospective case series from at a tertiary care center for treated patients with HPV-positive OPSCC presenting with oropharyngeal hemorrhage. Results Median time from completion of chemoradiation to first hemorrhagic event was 186 days (range 66-1466 days). Seven patients (58%) required intervention to secure their airway. All patients were evaluated for endovascular intervention, six (50%) were embolized. Eight patients (67%) had a second hemorrhagic event; median time to second bleed was 22 days (range 3-90 days). Conclusions Acute oropharyngeal hemorrhage is a sequelae following treatment for HPV-positive OPSCC. The majority of bleeds occurred within a year of completion of treatment. While more research is needed to determine optimal treatment paradigms, endovascular intervention should be considered, even if noninvasive imaging does not demonstrate active bleeding.
引用
收藏
页码:1079 / 1085
页数:7
相关论文
共 50 条
  • [31] Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline
    Margalit, Danielle N.
    Anker, Christopher J.
    Aristophanous, Michalis
    Awan, Musaddiq
    Bajaj, Gopal K.
    Bradfield, Lisa
    Califano, Joseph
    Caudell, Jimmy J.
    Chapman, Christina H.
    Garden, Adam S.
    Harari, Paul M.
    Helms, Amanda
    Lin, Alexander
    Maghami, Ellie
    Mehra, Ranee
    Parker, Lance
    Shnayder, Yelizaveta
    Spencer, Sharon
    Swiecicki, Paul L.
    Tsai, Jillian Chiaojung
    Sher, David J.
    PRACTICAL RADIATION ONCOLOGY, 2024, 14 (05) : 398 - 425
  • [32] Clinical outcomes of HPV-positive non-oropharyngeal squamous cell carcinoma: analysis of the NCDB
    Ko, H.
    Sacotte, R.
    Yu, M.
    Chen, S.
    Wieland, A.
    Witek, M.
    RADIOTHERAPY AND ONCOLOGY, 2017, 122 : 51 - 52
  • [33] MRI for Differentiation between HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Carcinoma: A Systematic Review
    Chen, Linda L.
    Lauwers, Iris
    Verduijn, Gerda
    Philippens, Marielle
    Gahrmann, Renske
    Capala, Marta E.
    Petit, Steven
    CANCERS, 2024, 16 (11)
  • [34] Prospective assessment of multiple HPV-positive oropharyngeal squamous cell carcinomas
    Faden, Daniel L.
    O'Boyle, Connor J.
    Lin, Derrick T.
    Deschler, Daniel G.
    Emerick, Kevin S.
    Varvares, Mark A.
    Faquin, William C.
    Sadow, Peter M.
    Richmon, Jeremy D.
    ORAL ONCOLOGY, 2021, 117
  • [35] Salivary HPV Persistence Following Treatment of Oropharyngeal Squamous Cell Carcinoma
    Quimby, Alexandra E.
    Lagiou, Pagona
    Purgina, Bibiana
    Corsten, Martin
    Johnson-Obaseki, Stephanie
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2022, 131 (10): : 1053 - 1059
  • [36] From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas
    Boscolo-Rizzo, Paolo
    Pawlita, Michael
    Holzinger, Dana
    CANCER TREATMENT REVIEWS, 2016, 42 : 24 - 29
  • [37] Multi-institutional analysis of outcomes following transoral surgery for HPV-positive oropharyngeal squamous cell carcinoma in elderly patients
    Jackson, Ryan S.
    Chen, Stephanie
    Last, Aisling
    Khan, Amish
    Kallogjeri, Dorina
    Van Abel, Kathryn M.
    Moore, Eric J.
    Pipkorn, Patrik
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (11): : 3933 - 3939
  • [38] Mapping the landscape of HPV integration and characterising virus and host genome interactions in HPV-positive oropharyngeal squamous cell carcinoma
    Xu, Shengming
    Shi, Chaoji
    Zhou, Rong
    Han, Yong
    Li, NianNian
    Qu, Chuxiang
    Xia, Ronghui
    Zhang, Chunye
    Hu, Yuhua
    Tian, Zhen
    Liu, Shuli
    Wang, Lizhen
    Li, Jiang
    Zhang, Zhiyuan
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (01):
  • [39] Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma
    Bauwens, Laurence
    Baltres, Aline
    Fiani, Danny-Joe
    Zrounba, Philippe
    Buiret, Guillaume
    Fleury, Bertrand
    Benzerdjeb, Nazim
    Gregoire, Vincent
    RADIOTHERAPY AND ONCOLOGY, 2021, 157 : 122 - 129
  • [40] The Role of Human Chorionic Gonadotropin Beta (hCGβ) in HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Carcinoma
    Sjoblom, Anni
    Carpen, Timo
    Stenman, Ulf-Hakan
    Jouhi, Lauri
    Haglund, Caj
    Syrjanen, Stina
    Mattila, Petri
    Makitie, Antti
    Hagstrom, Jaana
    CANCERS, 2022, 14 (12)